114 related articles for article (PubMed ID: 10472432)
21. Pituitary adenomas: the role of 111In-DTPA-octreotide SPET in the detection of minimal post-surgical residues.
Lauriero F; Pierangeli E; Rubini G; Resta M; D'Addabbo A
Nucl Med Commun; 1998 Dec; 19(12):1127-34. PubMed ID: 9885802
[TBL] [Abstract][Full Text] [Related]
22. Congenital gigantism due to growth hormone-releasing hormone excess and pituitary hyperplasia with adenomatous transformation.
Zimmerman D; Young WF; Ebersold MJ; Scheithauer BW; Kovacs K; Horvath E; Whitaker MD; Eberhardt NL; Downs TR; Frohman LA
J Clin Endocrinol Metab; 1993 Jan; 76(1):216-22. PubMed ID: 8421089
[TBL] [Abstract][Full Text] [Related]
23. Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients.
Minniti G; Jaffrain-Rea ML; Baldelli R; Ferretti E; Caracciolo B; Bultrini A; Gulino A; Tamburrano G
Clin Ter; 1997 Dec; 148(12):601-7. PubMed ID: 9528195
[TBL] [Abstract][Full Text] [Related]
24. Scintigraphic imaging of pituitary adenomas: an in vivo evaluation of somatostatin receptors.
Oppizzi G; Cozzi R; Dallabonzana D; Orlandi P; Benini Z; Petroncini M; Attanasio R; Milella M; Banfi G; Possa M
J Endocrinol Invest; 1998 Sep; 21(8):512-9. PubMed ID: 9801992
[TBL] [Abstract][Full Text] [Related]
25. Different responses of growth hormone secretion to guanfacine, bromocriptine, and thyrotropin-releasing hormone in acromegalic patients with pure growth hormone (GH)-containing and mixed GH/prolactin-containing pituitary adenomas.
Lamberts SW; Klijn JG; van Vroonhoven CC; Stefanko SZ
J Clin Endocrinol Metab; 1985 Jun; 60(6):1148-53. PubMed ID: 3923021
[TBL] [Abstract][Full Text] [Related]
26. 111Indium-pentetreotide pituitary scintigraphy and hormonal responses to octreotide in acromegalic patients.
Legovini P; De Menis E; Billeci D; Conti B; Zoli P; Conte N
J Endocrinol Invest; 1997; 20(7):424-8. PubMed ID: 9309542
[TBL] [Abstract][Full Text] [Related]
27. [Prediction of pharmacological effect of octreotide in acromegaly by means of 111In-pentetreotide scintigraphy and calculation of a pituitary uptake index].
Görges R; Cordes U; Engelbach M; Bartelt KM; Haberern G; Hey O; Beyer J; Bockisch A
Nuklearmedizin; 1997 Jun; 36(4):117-24. PubMed ID: 9289697
[TBL] [Abstract][Full Text] [Related]
28. The effect of the somatostatin analog SMS 201-995 on normal growth hormone secretion in the rat. A comparison with the effect of bromocriptine on normal prolactin secretion.
Lamberts SW; Verleun T; Zuiderwijk JM; Oosterom R
Acta Endocrinol (Copenh); 1987 Jun; 115(2):196-202. PubMed ID: 2885995
[TBL] [Abstract][Full Text] [Related]
29. Somatostatin receptor scintigraphy in pituitary adenomas: a somatostatin receptor density index can predict hormonal and tumoral efficacy of octreotide in vivo.
Duet M; Ajzenberg C; Benelhadj S; Lajeunie E; Lormeau B; Guillausseau PJ; Rohmer V; Vilain D; Mundler O; Warnet A
J Nucl Med; 1999 Aug; 40(8):1252-6. PubMed ID: 10450674
[TBL] [Abstract][Full Text] [Related]
30. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy.
Lamberts SW; Hofland LJ; de Herder WW; Kwekkeboom DJ; Reubi JC; Krenning EP
Front Neuroendocrinol; 1993 Jan; 14(1):27-55. PubMed ID: 8097480
[TBL] [Abstract][Full Text] [Related]
31. The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours.
Acosta-Gómez MJ; Muros MA; Llamas-Elvira JM; Ramírez A; Ortega S; Sabatel G; Ramos C; de la Riva-Aguilar A
Br J Radiol; 2005 Feb; 78(926):110-5. PubMed ID: 15681321
[TBL] [Abstract][Full Text] [Related]
32. Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal.
Sadoul JL; Thyss A; Freychet P
Acta Endocrinol (Copenh); 1992 Feb; 126(2):179-83. PubMed ID: 1543025
[TBL] [Abstract][Full Text] [Related]
33. Hormone secretion in vitro by plurihormonal pituitary adenomas of the acidophil cell line.
Asa SL; Kovacs K; Horvath E; Singer W; Smyth HS
J Clin Endocrinol Metab; 1992 Jul; 75(1):68-75. PubMed ID: 1352308
[TBL] [Abstract][Full Text] [Related]
34. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells.
Saveanu A; Lavaque E; Gunz G; Barlier A; Kim S; Taylor JE; Culler MD; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2002 Dec; 87(12):5545-52. PubMed ID: 12466351
[TBL] [Abstract][Full Text] [Related]
35. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
[TBL] [Abstract][Full Text] [Related]
36. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
[TBL] [Abstract][Full Text] [Related]
37. 111In-octreotide scintigraphy in pituitary adenomas.
Tofani A; Cucchi R; Pompili A; Carapella C; Crecco M; Mottolese M; Maini CL
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):94-7. PubMed ID: 9002760
[TBL] [Abstract][Full Text] [Related]
38. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
39. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
40. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
